Kids with asthma are more likely to be prescribed antibiotics, despite the fact that they don’t need them more than kids without asthma, according to a study that is slated to be presented at the European Respiratory Society International Congress. Researchers from Erasmus University in the Netherlands pointed out that it’s possible that asthma symptoms […]
Respiratory
Regeneron, Sanofi tout topline Ph3 data for injectable asthma drug
Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) touted data today from the pivotal Phase III trial of dupilumab in a group of patients with uncontrolled, persistent asthma. The drug is already approved for adults with certain forms of eczema. The two companies said they plan to seek FDA approval of dupilumab in asthma by the end of the year. […]
Pulmatrix licenses inhaled COPD drug to Vectura
Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura. The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said. “Vectura has deep experience with inhaled drugs and innovative dry powder delivery technologies which makes them an […]
Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide
Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease. The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity. The data showed […]
Janssen’s respiratory panel wins 510(k) clearance
Johnson & Johnson (NYSE:JNJ) subsidiary Janssen Diagnostics said today that it won 510(k) clearance from the FDA for its Idylla respiratory panel. The diagnostic test, developed in partnership with Biocartis Group, helps physicians identify viral respiratory infections, including infection from respiratory syncytial virus and influenza virus. The company’s assay uses nasopharyngeal swabs to collect samples and […]
Adherium wins 510(k) clearance for smart inhaler monitoring device
Adherium Ltd. (ASK:ADR) said today that it won 510(k) approval from the FDA for its inhaler monitoring device, SmartTouch for Symbicort. The device was cleared for use with AstraZeneca‘s (NYSE:AZN) Symbicort aerosol inhaler. The Melbourne, Australia-based company’s product installs directly onto a patient’s inhaler to monitor and boost medication adherence. The device records the time and […]
Propeller Health, GSK expand collaboration for connected inhaler
Propeller Health and GlaxoSmithKline (NYSE:GSK) said today that the two companies are planning to commercialize GSK’s Ellipta inhaler with Propeller’s clip-on medication sensor and software platform. The companies first announced their partnership in 2015 and in November last year the pair won 510(k) clearance from the FDA to market the Propeller plaftform with the Ellipta dry […]
Aradigm lands NIH grant for inhaled, liposomal products
Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin. The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company. The Phase II […]
Kaleo launches program to give Auvi-Q allergy devices to schools
Kaleo said today that it launched a new program to offer its epinephrine auto-injector, Auvi-Q, free-of-charge to all public elementary schools in the U.S. The program is slated to give up to four Auvi-Q cartons per school each academic year. Each carton has two auto-injectors and a training device. Kaleo’s emergency allergy auto-injector features voice […]
Teva wins FDA nod for Qvar RediHaler device
Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved its Qvar RediHaler breath-actuated inhaler for the maintenance treatment of asthma in patients ages 4 and older. The device, which is not indicated for acute bronchospasm, is slated to become commercially available during the first quarter of 2018. Unlike conventional metered-dose inhalers, the Qvar RediHaler does not […]